Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia

A Phase III, Prospective, Open-label, Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia Due to NDD-CKD or With Iron Deficiency Anemia Who Are Intolerant or Unresponsive to Oral Iron

Several clinical trials have been reported for ferric derisomaltose where it has been shown to be well tolerated and to improve markers of IDA. All clinical trials with ferric derisomaltose have been performed in adults, however, IDA is not specific to the adult population. In fact, children are likely to develop IDA due to their rapid growth.

The aim in this trial is to evaluate the efficacy and safety of intravenous (IV) ferric derisomaltose in children 0 to <18 years of age with IDA due to NDD-CKD or with IDA who are intolerant or unresponsive to oral iron .

The subjects will receive ferric derisomaltose/iron isomaltoside 1000 (Monoferric®/Monofer®), at single doses of 10 mg/kg or 20 mg/kg with a maximal dose of 1000 mg.

24 subjects will be part of a PK assessment, meaning that more blood samples will be drawn within the first week after treatment. The blood samples will be used for analysis of the amount of total iron in the blood from treatment is given to day 7.

For the individual subject, duration of the trial will be approximately 10 weeks (including a 14-day screening period) and each subject will attend 6-9 visits. Subjects who will be included in the PK assessments will attend 8 (subjects age 6 to <12 years old and 0 to <6 years old) or 9 (subjects age 12 to <18 years old) visits, while the other subjects will attend 6 visits.

Study Overview

• Status: Recruiting
• Conditions: Iron Deficiency, Anaemia in Children
• Intervention / Treatment: Drug: Ferric Derisomaltose

Detailed Description

This is a combined clinical pharmacology and phase III study. The study is a prospective, open-label, multi-center study. Children 0 to <18 years of age with iron deficiency anemia (IDA) with a) non-dialysis dependent chronic kidney disease (NDD-CKD) or b) who are intolerant or unresponsive to oral iron will be enrolled. The subjects will receive ferric derisomaltose/iron isomaltoside 1000 (Monoferric®) at single doses of 10 mg/kg or 20 mg/kg with a maximal dose of 1000 mg.

A total of 200 subjects will be enrolled. Of these will 24 be part of the PK assessment. PK-subjects will be included in cohorts of 4 with the oldest age group as the first and with ferric derisomaltose 10 mg/kg to be increased to 20 mg/kg for the next cohort. Thus 12 subjects will be treated with 10mg/kg and the remaining 188 subjects with 20mg/kg.

• Study Type: Interventional
• Enrollment (Estimated): 200
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Pharmacosmos A/S Clinical and Non-clinical Research; Phone Number: +4559485959; Email: info@pharmacosmos.com

Study Locations

• United States
  • Florida
    • Miami, Florida, United States, 33142
      • Recruiting
      • Pharmacosmos Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 17 years (Child)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Subjects <18 years
• Informed consent and child assent, as age-appropriate, obtained before any trial- related activities and willingness to participate. LAR of the subject must sign and date the ICF (according to local requirements). The child must sign and date the CAF or provide oral assent, if required according to local requirements
• IDA caused by different etiologies such as gastrointestinal disease, NDD-CKD, or other conditions leading to IDA
• Hb concentration less than the 5th percentile for age and sex-specific reference range (Appendix B)

• Subjects with NDD-CKD (a) or who are intolerant or unresponsive to oral iron (b):

  a) Subjects with NDD-CKD:

• TSAT ≤35 % or s-ferritin <100 ng/mL
• Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2

• If on ESA, receiving stable ESA regimen defined as dose adjustments no more than

  ± 20 % for ≥8 weeks prior to screening

  b) Subjects with documented history of intolerance or unresponsiveness to oral iron therapy for at least one month prior to trial enrolment.

• TSAT ≤20 % or s-ferritin <100 ng/mL

Exclusion Criteria:

• Anemia caused by factors other than IDA according to Investigator's judgment
• S-ferritin >600 ng/mL
• Hb ≤5.0 g/dL
• Iron overload or disturbances in utilization of iron (e.g. hemochromatosis and hemosiderosis)
• ALAT and/or ASAT >2 times upper limit of normal (e.g. decompensated liver cirrhosis or active hepatitis)
• Pregnant or nursing female subjects. In order to avoid pregnancy, female subjects of childbearing potential have to use adequate contraception (e.g. intrauterine devices, hormonal contraceptives, or double barrier method) or be abstinent during the whole trial period and 7 days after the last dosing. Childbearing potential refers to all female subjects ≥12 years old or <12 years old who have started menstruating
• Previous serious hypersensitivity reactions to any IV iron compounds including ferric derisomaltose
• Received an investigational drug within 30 days prior to screening
• Treatment with IV iron within 10 days prior to screening
• Treatment with blood transfusion, radiotherapy, chemotherapy or other drugs that suppress the bone marrow, and drugs which have anemia as side effect within 30 days prior to screening
• Planned elective surgery (or planned surgery during the trial period) where significant blood loss is expected within the last 30 days prior to screening
• Any non-viral infection (non-viral infection that has been fully treated before the baseline visit is accepted)
• Any other laboratory abnormality, medical condition, or psychiatric disorders which, in the opinion of the Investigator, will put the subject's disease management at risk or may result in the subject being unable to comply with the trial requirements

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Ferric Derisomaltose; All subjects (a total of 200) will be treated with Ferric Derisomaltose. 12 subjects (half of the 24 subjects participating in the PK-part of the trial) will be treated with 10mg/kg while the remaining subjects will be treated with 20 mg/kg. .	Drug: Ferric Derisomaltose; All subjects will be treated with Ferric derisomaltose 20 mg/kg at baseline visit except for 12 subjects included in the PK-group, who will be treated with 10 mg/kg; Other Names: Monofer®, Monoferric®

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of subjects with a Hb increase of ≥1 g/dL (NDD-CKD) or 2 g/dL (intolerant or unresponsive to oral iron). Measurement by bloodsample.	Hb (g/dL), measurement by bloodsample analysis	From baseline at any time from week 1 to week 8

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to increase Hb ≥1 g/dL (NDD-CKD) or 2 g/dL (intolerant or unresponsive to oral iron). Measurement by bloodsample.	Hb (g/dL), measurement by bloodsample analysis	From baseline at any time from week 1 to week 8
Incidence of subjects who achieve a serum (s-) ferritin of ≥100 ng/mL. Measurement by bloodsample.	s-ferritin (ng/mL), measurement by bloodsample analysis	At weeks 1, 2, 4, and 8
Incidence of subjects who achieve a TSAT of ≥35 % (NDD-CKD) or ≥20 % (intolerant or unresponsive to oral iron). Measurement by bloodsample.	TSAT (%), measurement by bloodsample analysis	At weeks 1, 2, 4, and 8
Total iron PK parameters: AUC0-∞	Total iron (µg/dL), measurement by bloodsample analysis	From baseline to day 7
Total iron PK parameters: AUC0-t	Total iron (µg/dL), measurement by bloodsample analysis	From baseline to day 7
Total iron PK parameters: Cmax	Total iron (µg/dL), measurement by bloodsample analysis	From baseline to day 7
Total iron PK parameters: Tmax	Total iron (µg/dL), measurement by bloodsample analysis	From baseline to day 7
Total iron PK parameters: Ke	Total iron (µg/dL), measurement by bloodsample analysis	From baseline to day 7
Total iron PK parameters: T½	Total iron (µg/dL), measurement by bloodsample analysis	From baseline to day 7
Total iron PK parameters: CL	Total iron (µg/dL), measurement by bloodsample analysis	From baseline to day 7
Total iron PK parameters: Vd	Total iron (µg/dL), measurement by bloodsample analysis	From baseline to day 7
Type and incidence of AEs	Any AE	From baseline to week 8
Serious or severe hypersensitivity reaction	Any serious or severe hypersensitivity reaction	From treatment (Baseline) to 24 hours

Collaborators and Investigators

• Sponsor: Pharmacosmos A/S

Study record dates

Study Major Dates

• Study Start (Actual): November 28, 2022
• Primary Completion (Estimated): April 30, 2027
• Study Completion (Estimated): April 30, 2027

Study Registration Dates

• First Submitted: November 16, 2021
• First Submitted That Met QC Criteria: December 20, 2021
• First Posted (Actual): January 5, 2022

Study Record Updates

• Last Update Posted (Actual): August 7, 2026
• Last Update Submitted That Met QC Criteria: August 6, 2026
• Last Verified: August 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Metabolic Diseases; Iron Metabolism Disorders; Nutritional and Metabolic Diseases; Iron Deficiencies; ferric derisomaltose
• Other Study ID Numbers: P-Monofer-PED-01; U1111-1266-9073 (Registry Identifier: WHO)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No